Aileron Therapeutics CMO Vojislav Vukovic departs; severance agreement reached

Rein Therapeutics, Inc.

Chief Medical Officer Vojislav Vukovic, M.D., Ph.D. separated from Aileron on July 8, 2022.
Separation was not due to any disagreement with the company regarding operations, policies, or practices.
Severance includes nine months of semi-monthly salary continuation and COBRA premium payments.
Separation agreement contains customary release of claims, non-solicit, non-disparagement, and cooperation covenants.
No successor or interim CMO has been announced as of the filing date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vojislav Vukovic

Chief Medical Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2022-07-08
Filed: July 8, 2022, 7:59 PM ET

On July 8, 2022, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Separation and Release of Claims Agreement with Vojislav Vukovic, M.D., Ph.D. (the “Separation Agreement”), which provides for Dr. Vukovic’s separation of employment as Senior Vice President, Chief Medical Officer of the Company, effective July 8, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Vojislav Vukovic departed as Chief Medical Officer at Rein Therapeutics, Inc..

Action: separated
Role: Chief Medical Officer

Exact text from the filing

On July 8, 2022, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Separation and Release of Claims Agreement with Vojislav Vukovic, M.D., Ph.D. (the “Separation Agreement”), which provides for Dr. Vukovic’s separation of employment as Senior Vice President, Chief Medical Officer of the Company, effective July 8, 2022

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-190531

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.